Life Sciences
Market Access, HTA & Reimbursement Strategy
Zinergy supports life sciences organisations in developing and aligning integrated market access strategies for their products, taking into account AMNOG, EU HTA and reimbursement requirements.
We bring together requirements, stakeholders and workstreams to guide products and procedures through complex assessment and decision-making processes towards robust and achievable outcomes.
From Evidence to Access
Successful market access requires more than a strong clinical profile. It requires the early alignment of evidence, value, assessment and reimbursement requirements, payer expectations and commercial priorities.
Zinergy supports clients in preparing for AMNOG and EU HTA by structuring requirements, clarifying responsibilities and coordinating the relevant workstreams. We help translate evidence and assessment requirements into clear strategic priorities and actionable next steps.
Who We Support
We support pharmaceutical, biotechnology and healthcare organisations in navigating complex Market Access, HTA and reimbursement requirements in Germany and Europe.
Market Access Strategy
We develop clear and actionable market access strategies that align product development, evidence generation, assessment requirements, reimbursement considerations and commercial objectives.
Our Services Include:
Early market access strategy
Market, payer and HTA landscape assessment
Strategic positioning of products and indications
Market access roadmaps
Alignment of strategic priorities and responsibilities
AMNOG and EU HTA
We support clients in preparing for national and European HTA requirements and in aligning evidence, responsibilities and workstreams with relevant reimbursement considerations.
Our Services Include:
Value dossier strategy and development
Evidence-gap analysis and evidence planning
Payer-relevant evidence assessment
Assessment of risks, uncertainties and reimbursement implications
AMNOG strategy and process preparation
G-BA readiness
EU HTA readiness and strategic preparation
Interim Leadership and Senior Advisory
We provide experienced leadership and targeted senior support when internal capacity, specialist expertise or independent strategic guidance is required.
Our Services Include:
Interim Market Access and HTA leadership
Senior advisory on Market Access, HTA and reimbursement-related questions
Programme and workstream leadership
Management of AMNOG and HTA-related deliverables
Coordination of relevant responsibilities and interfaces
Independent review of strategies and deliverables
Practice Leadership
Dr. Elke Ziegler
Director, Life Sciences
Market Access, HTA & Reimbursement Strategy
Dr. Elke Ziegler leads Zinergy’s Life Sciences practice. She advises life sciences organisations on Market Access, AMNOG, HTA, reimbursement and evidence strategy in Germany and Europe.
Her work combines extensive industry experience with an in-depth understanding of healthcare assessment and decision-making processes, enabling her to structure complex requirements and develop clear strategic pathways through critical Market Access and HTA processes.
Discuss your market access challenge
Whether you are preparing an asset for HTA, reviewing an evidence strategy, planning market access in Germany or Europe, or require experienced interim leadership, we provide focused senior support tailored to your situation.